Research Paper Advance Articles pp 23872—23888

Apigenin-7-O-β-D-(-6”-p-coumaroyl)-glucopyranoside treatment elicits a neuroprotective effect through GSK-3β phosphorylation-mediated Nrf2 activation

Figure 7. PI3K inhibitors wortmannin and LY294002 or Nrf2 knockdown reversed the neuroprotection induced by APG treatment. Representative TTC staining images (A), neurological behavior results (B), and infarct volume results (C) are presented. Both the inhibition of GSK-3β phosphorylation induced by PI3K inhibitors and the Nrf2 knockdown produced by siRNA reversed the neurobiological behavior improvement and increased the infarct volume compared with the APG group (n = 7 per group). * P < 0.05 vs. I/R+APG group. I/R = ischemia/reperfusion.